Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 13/20 | 0.77 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.35 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146251 | 1.00 | CHRNA7 (0.77) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1146254 | 1.00 | CHRNA7 (0.77) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1908597 | 1.00 | CHRNA7 (0.77) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Methane SCHEMBL17004210 | 0.99 | CHRNA7 (0.76) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Abt-107 SCHEMBL29364159 | 0.87 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Abt-107 SCHEMBL373047 | 0.87 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Abt-107 SCHEMBL527745 | 0.87 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Abt-107 SCHEMBL1542259 | 0.87 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Abt-107 SCHEMBL31393053 | 0.87 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1908561 | 0.86 | CHRNA7 (0.57) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480228-B1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2016-11-16 | — | — | EP | claimed |
| US-8637517-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-01-28 | — | — | US | claimed |
| US-20120022074-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-26 | — | — | US | claimed |
| US-8048885-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | claimed |
| EP-1966209-B1 | [ 1H- INDOL- 5 -YL) -HETEROARYLOXY] - (1-AZA-BICYCLO [3.3.1] NONANES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENERATIVE DISORDERS | NOVARTIS AG (CH) | 2011-10-19 | — | — | EP | claimed |
| EP-2361914-A1 | [(1H-INDOL-5-YL)-HETEROARYLOXY]-(1-AZA-BICYCLO[3.3.1]NONANES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENRATIVE DISORDERS. | Novartis AG (CH) | 2011-08-31 | — | — | EP | claimed |
| US-20100179160-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2010-07-15 | — | — | US | claimed |
| US-20080293731-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | claimed |
| EP-1966209-A1 | [ 1H- INDOL- 5 -YL) -HETEROARYLOXY] - (1-AZA-BICYCLO [3.3.1] NONANES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENERATIVE DISORDERS. | Novartis AG (CH) | 2008-09-10 | — | — | EP | claimed |
| WO-2007068476-A1 | [ (1H- INDOL- 5 -YL) -HETEROARYLOXY] - (1-AZA-BICYCLO [3.3.1] NONANES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENRATIVE DISORDERS. | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | claimed |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2025-02-04 | — | — | US | disclosed |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2022-10-06 | — | — | US | disclosed |
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-07-07 | — | — | US | disclosed |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-11311525-B2 | Use of alpha 7 nicotinic acetylcholine receptor agonists | NOVARTIS AG (CH) | 2022-04-26 | — | — | US | disclosed |
| US-20080293731-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| US-20080293731-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1966209-A1 | [ 1H- INDOL- 5 -YL) -HETEROARYLOXY] - (1-AZA-BICYCLO [3.3.1] NONANES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENERATIVE DISORDERS. | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068476-A1 | [ (1H- INDOL- 5 -YL) -HETEROARYLOXY] - (1-AZA-BICYCLO [3.3.1] NONANES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENRATIVE DISORDERS. | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007068476-A1 | [ (1H- INDOL- 5 -YL) -HETEROARYLOXY] - (1-AZA-BICYCLO [3.3.1] NONANES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENRATIVE DISORDERS. | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311525-B2 | Use of alpha 7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA1, CHRNA5 | CHRNA7 1/4885CHRNB2 16/4885CHRNA4 4/4885 |
| US-20120022074-A1 | ORGANIC COMPOUNDS | TPMT, DNMT1, DNMT3L | CHRNA7 254/4885CHRNB2 977/4885CHRNA4 388/4885 |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885CHRNB2 9/4885CHRNA4 2/4885 |
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA1, CHRNA4 | CHRNA7 1/4885CHRNB2 16/4885CHRNA4 3/4885 |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885CHRNB2 9/4885CHRNA4 2/4885 |
| US-20080293731-A1 | Organic Compounds | CYP1B1, CYP2B6, UGT2B7 | CHRNA7 1836/4885CHRNB2 3288/4885CHRNA4 2734/4885 |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885CHRNB2 9/4885CHRNA4 2/4885 |
| US-20100179160-A1 | ORGANIC COMPOUNDS | TPMT, DNMT1, DNMT3L | CHRNA7 254/4885CHRNB2 977/4885CHRNA4 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.